

**From:** [REDACTED]

**Sent:** Friday, April 23, 2010 12:13 PM

**To:** [REDACTED]

**Subject:** Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer

Dear [REDACTED]

I hope you are well. We have noticed that new analyses have been produced in the reply to our points of clarification. However, the Excel spreadsheets regarding these new cost effectiveness analyses were not presented and it would be helpful for the ERG to have these.

We would appreciate it if you could provide us with:

- 1) the Excel spreadsheets of the revised model presented in response to question B1 (results in Table 7)
- 2) the Excel spreadsheets of the revised model presented in response to question B2 (results in Tables 8 and 9)

For each of these, it would be useful to have one file regarding the base case where list prices are considered, and one file regarding the base case scenario considering the PASA price for paclitaxel and capping scheme for bevacizumab.

In order for the ERG to have sufficient time for consideration, please could provide the spreadsheets as soon as possible; please let us know if you anticipate any problems/delays in getting them to us.

Thank you.

Best wishes,

[REDACTED]